ICOS ligand
别名 | B7 homolog 2, B7-H2, B7-related protein 1, B7RP-1, ICOS-L |
---|---|
Compound Class | Peptide |
变动原因 |
Endogenous ligand for ICOS that is expressed on the surface of antigen presenting cells. Inhibiting the ICOS/ICOSL axis is predicted to provide anti-inflammatory activity applicable for the treatment of autoimmune diseases. The ICOSL protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590. The anti-ICOSL monoclonal antibody MEDI5872 (AMG557) is being evaluated in Phase 2 clinical trial in patients with primary Sjögren's syndrome (NCT02334306). Phase 1 trials of the same biologic in systemic lupus erythematosus (SLE) and psoriasis were terminated. |
Species |
Human |
Related Product | ICOS ligand |
Summary
基因/前体 |
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
是否批准为药物? | |||||||||||
IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
别名 | B7 homolog 2, B7-H2, B7-related protein 1, B7RP-1, ICOS-L |
生物活性
生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
---|
临床资料
作用机制与药效学效应 |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants |
---|
结构
Peptide Sequence | MRLGSPGLLFLLFSSLRADTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWSILAVLCLLVVVAVAIGWVCRDRCLQHSYAGAWAVSPETELTGHV |
---|---|
Post Translation Modifications |
Signal peptide 1-18 Mature peptide 19-302 Transmembrane region 257-277 |